New clinical trial data shows that the medication Xywav significantly reduced the long sleep duration and excessive daytime sleepiness that are typical hallmarks of the sleep disorder idiopathic hypersomnia.
Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
A common concern in narcolepsy and idiopathic hypersomnia is a feeling of having little control over symptoms, which can lead to despair. But disorders of excessive sleepiness do have both medication and non-medication treatment approaches.
Highlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read More
Marketed by Jazz Pharmaceuticals, Xywav is for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read More
Sleep professionals and the general public have misperceptions about the neurological sleep disorder. How many did you believe?
Read MoreSleep Review annually rounds up the sleep medicine devices, pharmaceuticals, and more that earned US Food and Drug Administration clearance.
Read More
The FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc’s NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read MoreSolriamfetol, a dopamine and norepinephrine reuptake inhibitor, offers short-term improvements in health-related quality of life (HRQoL), and work productivity in people with narcolepsy, according to study results published in Sleep Medicine.
Read MoreJazz Pharmaceuticals plc submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on January 21, 2020, seeking marketing approval for JZP-258, an investigational medicine for the treatment of...
Read More
Investigators surveyed health care providers as well as people with narcolepsy, and multiple...
Read MoreThe European Commission has approved Jazz Pharmaceuticals plc’s Sunosi (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or...
Read More
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...
Read MoreSolriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA), according to a statement from the...
Read More
Positive data from the Phase 3 study of Jazz Pharmaceuticals plc’s investigational medicine,...
Read MoreThe U.S. Drug Enforcement Agency (DEA) has designated Jazz Pharmaceuticals plc’s solriamfetol, also known as Sunosi, as a Schedule IV medicine, which is its category for drugs with a low potential for abuse and low risk of...
Read MoreProject Sleep, a national organization that aims to educate individuals about the importance of sleep health, awarded 18 recipients with a 2019 Jack & Julie Narcolepsy Scholarship. This is the largest class of recipients to...
Read MoreFourteen abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial focusing on sodium oxybate will be presented at SLEEP 2019 San Antonio from June 8-12, 2019. “Jazz is committed to...
Read More